Objective: van't Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with node-negative breast cancer. Methods: Frozen tumour samples from 102 eligible node-negative breast cancer patients aged 70 or younger were characterized with the MammaPrint array. The patients were treated with breast-conserving therapy or mastectomy with axillary lymph node dissection between December 1998 and August 2001. About 73 percent received adjuvant hormonal therapy and 28 percent received adjuvant chemotherapy. The gene expression profiles obtained by MammaPrint classified the patients as high-or low-genomic risk. The median follow-up was 7.1 years. Results: Among the 102 patients, 20 (20%) were classified as low-genomic risk and 82 (80%) were classified as high-genomic risk. The probability of distant metastasis-free survival at five years was 100% for the low-risk group and 94% for the high-risk group. Conclusions: The 70-gene MammaPrint prognosis profile accurately identified Japanese breast cancer patients at low risk of developing recurrences. In fact, 100% of the individuals in the low-risk category remained metastasis-free for the duration of the observation period.
INTRODUCTION
Breast cancer is the most common malignancy in women, not only in Western countries but also in Japan (1) . More than half of newly diagnosed breast cancer patients have no axillary lymph node involvement. There is strong evidence that the average Japanese lymph node-negative breast cancer patient tends to have a better prognosis than her Western counterpart (2) . Although some cancer patients who are negative for axillary lymph node involvement may benefit from adjuvant chemotherapy (3), a large number of patients would not recur even without chemotherapy.
Currently, adjuvant chemotherapy for patients with lymph node-negative breast cancer is usually administered based on the St Gallen classification (4, 5) . However, use of the St Gallen classification may lead to overtreatment in clinical practice. Since Japanese node-negative breast cancer patients tend to have better prognoses than their Western counterparts, it is likely that Japanese patients receive unnecessary chemotherapy more frequently than Western patients do, while the incidence and severity of adverse effects of chemotherapy is the same in both groups.
Genomic microarrays allow the identification of gene activity patterns that can further sub-classify tumours (6) and reveal their clinically relevant biological properties. To date, a number of commercialized multigene prognostic and predictive tests have been developed, including Oncotype DX (Genomic Health, Redwood City, CA, USA) and MammaPrint (MMP) (Agendia, Amsterdam, The Netherlands). Oncotype DX has been endorsed as a tumour marker by the American Society of Clinical Oncology. It has further been endorsed by the breast cancer panel of the National Comprehensive Cancer Network as an aid in decision-making regarding adjuvant chemotherapy in patients with oestrogen receptor(ER)-positive, node-negative breast cancer (7) . MMP was generated using breast cancer patients who showed no involvement of axillary lymph nodes and who were 54 years old or younger (8) . These patients were treated at the Netherlands Cancer Institute (NKI) (8) . The MMP's prognostic signature was found to correlate significantly with patient outcome. This tool was further validated in several patient groups in European countries (9, 10) , and it was approved by the United States Food and Drug Administration. Recently, MMP performed well for patients in TRANSBIG (10) and at the Massachusetts General Hospital Cancer Center (MGH) (11) .
Gene-expression profiles of breast cancer cells may differ with the ethnicity of the patient, and it remains unknown how effective MMP will prove to be for different populations and races. Breast cancer is rarer in Japanese women than in women from Western countries (particularly in postmenopausal women), and it tends to have a better prognosis (12) . Furthermore, the incidence of ER-positive breast cancer in postmenopausal Japanese women is much lower than that in Western countries. As evidenced by Japanese patients' better prognosis, it is possible that the usefulness of a prognostic evaluation tool can differ between races. In order to explore the effectiveness of this prognostic evaluation tool, we used it to retrospectively analyse stored samples from Japanese lymph node-negative breast cancer patients and compared the MMP results to the patients' actual long-term outcomes.
PATIENTS AND METHODS

PATIENT SELECTION
Breast tumours from 380 women were selected from the fresh-frozen tissue bank of the Osaka Medical Center for Cancer and Cardiovascular Diseases (OMCCCD). These patients had been treated between December 1998 and August 2001. Of these 380 patients, 367 (96.6%) were assayable with mRNA. From the study we excluded patients older than 70 years, and those with axillary lymph node involvement or T4 tumour or pure ductal carcinoma in situ. We further excluded patients with prior malignancies other than non-melanoma skin cancers. Of the 367 initial samples, 117 patients met all the requirements and were eligible. Clinicopathological data and follow-up information were retrieved from medical records (through October 2008). Written informed consent has been obtained from all patients regarding the use of their tumour materials and medical information, and our institutional review board approved this study.
All patients had been treated by modified radical mastectomy or breast-conserving surgery, including dissection of the axillary lymph nodes followed by radiotherapy if needed.
We recorded patient age, calendar year of diagnosis, surgery type, tumour characteristics (size, grade, histological type and ER status), nodal status, radiation treatment and hormonal therapy or chemotherapy. Clinical follow-up data was also recorded, including local, locoregional and distant recurrences, second primary malignancies, and date of last visit or death.
HISTOPATHOLOGICAL EVALUATION
Histological grade was determined according to the modified Scarff -Bloom -Richardson criteria (13) . ER and progesterone receptor (PgR) status was determined by immunohistochemistry, and tumours with 10% or more positively stained tumour cells were classified as positive for ER or PgR. Basically, adjuvant hormonal therapy was recommended for patients with ER and/or PgR-positive tumors.
ISOLATION OF RNA AND MICROARRAY EXPRESSION PROFILING
Tumours were snap-frozen in liquid nitrogen within 1 h after surgery and stored at 2808C. Frozen tumour samples were evaluated for MammaPrint TM (FDA 510(K) cleared) at Agendia's laboratories (ISO17025-certified and CLIA accredited, Amsterdam, the Netherlands). The samples were evaluated blind as to clinical origin, as previously described (8, 14) . Only tumours with at least 30% tumour cells were subjected to RNA isolation and microarray profiling. Microarray profiling was successful for 102 (87.2%) of the 117 eligible samples. The 15 failures may have been owing to complications during shipment of RNA from Japan to Agendia. Total RNA was isolated with Trizol reagent, dissolved in RNase-free water and subsequently treated with DNase and labelled. Labelled cRNAs were hybridized to the custom-designed MMP microarray in parallel with the standard breast cancer reference pool (14) .
MMP TUMOUR CLASSIFICATION
Tumours were classified based on the previously reported 70-gene classification model (8) . Briefly, for each of the 102 tumours, we calculated the cosine correlation coefficient of the expression level of the 70 prognosis genes using the MMP template. Tumours with a correlation coefficient above the threshold were classified as having a good prognosis signature, whereas all other tumours were classified as having a poor prognosis signature.
ST GALLEN TUMOUR CLASSIFICATION
Using the 1998 version of the St Gallen risk categories (4), low clinical-risk tumours were defined as either ER-positive or PgR-positive or both. Low-risk tumours were all 1 cm or smaller, grade 1, and from patients 35 years of age or over. All other tumours were classified as having moderate or high risk of distant metastasis and death.
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The most recent version (2009) of the St Gallen risk categories (5) designates somewhat different indications for solitary endocrine therapy for patients with ER-positive and HER2-negative disease (i.e. the low clinical-risk group). These are high expression of ERs and PgRs (e.g. .50%
FOLLOW-UP
Patients received a physical examination and blood tests that included CA15-3 and CEA every 3 -6 months for 5 years postoperatively, and annually thereafter. Mammograms and chest X-rays were obtained annually after surgery. The median follow-up period for the 102 patients was 7.1 years (range: 0.5-9.8 years).
STATISTICAL ANALYSIS
Correlations between the MMP risk category and various clinicopathological parameters were assessed using x 2 tests and Fisher's exact tests. Metastasis-free survival curves were calculated by the Kaplan -Meier method. All statistical tests and P values were two-tailed and P values of ,0.05 were considered significant. All calculations were performed with the Stat View 5.0.
RESULTS
The characteristics of the 102 patients examined in this study are shown in Table 1 . In this sample group, 82 (80.4%) patients were classified as belonging to the high-risk group, and 20 (19.6%) were in the low-risk group. The highrisk group patients showed significantly fewer ER-and PgR-positive tumours and more frequently exhibited grade 3 tumours (ER-positive: 40.2% vs. 95.0%, P ¼ 0.001; PgR-positive: 28.0% vs. 85.0%, P , 0.001; grade 3: 60.0% vs. 15.0%, P , 0.001; Table 1 ). Data on HER2/neu status were not routinely assessed in this study population; therefore, we could not assess the association of HER2/neu status with MMP classification.
Distant metastases were found in eight patients (7.8%). All the patients with metastases were in the high-risk group. The Kaplan -Meier plot for distant metastasis-free survival is shown in Fig. 1 . Negative predictive value (NPV) was quite high (100%, 20/20), while positive predictive value (PPV) was quite low (9.8%, 8/82; Table 2 ). All 10 patients who showed recurrence at any site were in the high-risk group.
Based on the St Gallen 1998 risk categories (used during this patient treatment period), all 102 patients in the OMCCCD cohort were classified as intermediate-or high- Percentages may not sum to 100% owing to missing data. OMCCCD, Osaka Medical Center for Cancer and Cardiovascular Diseases; ER, estrogen receptor; PgR, progesterone receptor.
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MammaPrint in a Japanese population risk ( Table 2 ). The latest St Gallen risk categories (2009) uses more refined criteria to define the low-risk group, and it classifies seven of these patients (7%) as low-risk. This number is still lower than the number characterized by MMP as low-risk (7 of 100 vs. 20 of 102; P ¼ 0.009, x 2 test). We then compared our results with previous retrospective studies. Table 3 shows PPVs and NPVs derived from the OMCCCD and other published reports. The PPVs of the OMCCCD and MGH cohorts were lower than those of the NKI and TRANSBIG cohorts were. Moreover, the number of individuals in the low-risk group in the OMCCCD and MGH cohorts were smaller than in the NKI and the TRANSBIG cohorts. This tendency of the OMCCCD cohort was consistent with patients restricted to the age group (54 years or younger) of the NKI and TRANSBIG cohorts (14 out of 58 patients characterized as low-risk).
DISCUSSION
MMP validations have previously been conducted in Western countries (8 -11) . This report is the first retrospective MMP study focused on Asian (and specifically Japanese) women with breast cancer. MMP accurately identified a group of Japanese breast cancer patients with no recurrence of cancer. The major characteristics of the OMCCCD cohort were an infrequency of low-risk classifications and low PPV owing to infrequent distant metastasis. These characteristics were shared with the MGH cohort, and were therefore derived in part from advanced age and systemic therapy. However, because this low incidence in the OMCCCD cohort was also observed in patients younger than 54 years, racial differences had some effects on the differences between the study cohorts.
It is unclear whether MMP is purely prognostic or predictive for the treatment in this study. However, because almost all breast cancer patients are recently treated with adjuvant therapy, it is practically infeasible to answer this question.
In Japan, the St Gallen risk categories are the standard for clinicopathological risk assessment. In the OMCCCD cohort, no patient was classified as low-risk based on the St Gallen 1998 risk categories, implying that chemotherapy should accompany all cases where tamoxifen was recommended. This is consistent with the conclusions of Percentages may not sum to 100% owing to missing data. NPV, negative predictive value; PPV, positive predictive value; DM, distant metastases, DF, disease free; MMP, MammaPrint. 
